This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- Christopher Sinsabaugh⇑
- Address for Correspondence: Christopher Sinsabaugh, 350 W. 11th St Rm 6027, Indianapolis, IN, 46202, 317-4491-6999, casinsab{at}iupui.edu
Abstract
A case of therapy-related myelodysplastic syndrome (t-MDS) with unusual cytogenetics is presented. While therapy related myeloid neoplasms account for 10-20% of all myeloid neoplasms, 90% of therapy related myelodysplastic syndromes(MDS) present with a del(7q) or a del(5q) and fewer than 1% present with a del(20q). In this case, the common cytogenetic pattern of either del(7q) or del(5q) is absent while presenting with an abnormal del(20q). Also demonstrated is the potently poor prognostic indicator of cytomegalovirus (CMV) seropositivity, even when seropositivity is matched between donor and recipient of hematopoietic stem-cell transplant. The patient also continues to demonstrate the inherent dangers of a stem-cell transplant, presenting with graft-versus-host disease (GvHD) while being a haploidentical 10 out of 10 HLA match to the allogeneic stem cell donor.
- INDEX TERMS
- therapy-related myeloid neoplasm
- therapy related myelodysplastic syndrome(t-MDS)
- cytomegalovirus(CMV)
- Graft-versus-host disease (GvHD)
- deletion of the long arm of chromosome 20(del(20q))
- © Copyright 2011 American Society for Clinical Laboratory Science Inc. All rights reserved.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.